|
Delayed
Nasdaq
11:16:24 2026-10-29 am EDT
|
5-day change | 1st Jan Change | ||
| 10.57 USD | -0.47% |
|
+1.24% | +71.87% |
| Oct. 12 | ImmuCell Q3 Preliminary Sales Rise | MT |
| Oct. 12 | Immucell Corporation Reports Preliminary Unaudited Sales Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 96.45M | - | - | - | - | - |
| 1,148B | |||||
| 652B | |||||
| 505B | |||||
| 384B | |||||
| 348B |
- Stock Market
- Stocks
- ICCC Stock
- Charts ImmuCell Corporation
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
